Alpha methylacyl a coenzyme racemase detection
A method of detecting the presence or absence of alpha methylacyl A coenzyme racemase (AMACR) is provided. In one embodiment of the method, a fluid including a secretion chosen from at least one of a prostate secretion or a secretion from an accessory glad or a cellular component of the fluid is obtained from a subject. The fluid is contacted with a reagent for detecting AMACR under conditions such that the reagent detects AMACR in the semen. The level of AMACR is determined such as by comparing it to a standard curve. The fluid can be semen or a prostate secretion or another fluid. A kit that can be used with the method is also provided.
1. A method of detecting the presence of alpha methylacyl A coenzyme racemase (AMACR) in a semen sample, comprising:
a) obtaining a semen sample from a subject; and
b) contacting the semen sample with a first antibody able to form a complex with AMACR, wherein the antibody is immobilized on a solid phase support or carrier, and
c) detecting an amount of the antibody-AMACR complex in the semen sample, wherein the amount of AMACR complex is a measure of an amount of AMACR in the semen sample; and wherein the amount of complex detected is indicative of a diagnosis of prostate cancer, a precancerous condition, or a prognosis of prostate cancer in the subject.
2. The method of claim 1 , wherein a level of AMACR in the semen sample is determined by comparing it to a standard curve from purified AMACR protein.
3. The method of claim 1 , wherein the presence of AMACR in the semen sample at a level above an age-appropriate minimum threshold level is indicative of a diagnosis of prostate cancer or a precancerous prostate condition in the subject.
4. The method of claim 1 , wherein the antibody comprises a label selected from the group consisting of an enzyme, a radioactive label, a fluorescent label, a fluorescence emitting metal, a chemiluminescent label, a chromophoric label, and a bioluminescent label.
5. The method of claim 1 , wherein the detecting the level of AMACR further comprises a second antibody specific to AMACR.
6. The method of claim 5 , wherein the detecting further comprises providing a third antibody, wherein at least one of the second and third antibody includes a label.